Circulating eosinophil levels and lung function decline in stable chronic obstructive pulmonary disease: a retrospective longitudinal study

Whether blood eosinophils (bEOS) in chronic obstructive pulmonary disease (COPD) are associated with disease progression is a topic of debate. We aimed to evaluate whether the differential white blood cell (WBC) count, symptoms and treatment may predict lung function decline and exacerbations in COP...

Full description

Saved in:
Bibliographic Details
Published in:Jornal brasileiro de pneumologia 2022, Vol.48 (6), p.e20220183-e20220183
Main Authors: Ferrari, Marcello, Pizzini, Michela, Cazzoletti, Lucia, Ermon, Valentina, Spelta, Francesco, De Marchi, Sergio, Carbonare, Luca Giuseppe Dalle, Crisafulli, Ernesto
Format: Article
Language:eng ; por
Subjects:
Humans
Longitudinal Studies
Lung
Pulmonary Disease, Chronic Obstructive
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Whether blood eosinophils (bEOS) in chronic obstructive pulmonary disease (COPD) are associated with disease progression is a topic of debate. We aimed to evaluate whether the differential white blood cell (WBC) count, symptoms and treatment may predict lung function decline and exacerbations in COPD patients. We retrospectively examined stable COPD patients with a minimum follow-up of 3 years at our outpatients' clinic. We collected information about lung volumes (FEV1, FVC), the total and differential WBC count, acute exacerbations of COPD (number in the 12 months before the beginning of the study=AE-COPD-B, and during the follow-up=AE-COPD-F), smoking status and treatment. FEV1 decline and AE-COPD-F were described by using a generalized linear model and a 2-level random intercept negative binomial regression, respectively. The models included eosinophil and neutrophil counts as potential predictors and were adjusted by sex, age, smoking status, AE-COPD-B, treatment with bronchodilators and inhaled corticosteroids (ICS). Sixty-eight patients were considered, 36 bEOS- (
ISSN:1806-3756
1806-3756
DOI:10.36416/1806-3756/e20220183